| Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5560 | 2017 |
| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3795 | 2019 |
| Chimeric antigen receptor T-cell therapy—assessment and management of toxicities SS Neelapu, S Tummala, P Kebriaei, W Wierda, C Gutierrez, FL Locke, ... Nature reviews Clinical oncology 15 (1), 47-62, 2018 | 2331 | 2018 |
| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017 | 1684 | 2017 |
| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 1180 | 2022 |
| Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 713 | 2020 |
| Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial JR Westin, F Chu, M Zhang, LE Fayad, LW Kwak, N Fowler, J Romaguera, ... The lancet oncology 15 (1), 69-77, 2014 | 654 | 2014 |
| Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ... Nature medicine 26 (12), 1878-1887, 2020 | 484 | 2020 |
| Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma MR Bishop, M Dickinson, D Purtill, P Barba, A Santoro, N Hamad, K Kato, ... New England Journal of Medicine 386 (7), 629-639, 2022 | 479 | 2022 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 457 | 2021 |
| Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma DM Kurtz, F Scherer, MC Jin, J Soo, AFM Craig, MS Esfahani, JJ Chabon, ... Journal of Clinical Oncology 36 (28), 2845-2853, 2018 | 448 | 2018 |
| Double hit lymphoma: the MD A nderson C ancer C enter clinical experience Y Oki, M Noorani, P Lin, RE Davis, SS Neelapu, L Ma, M Ahmed, ... British journal of haematology 166 (6), 891-901, 2014 | 439 | 2014 |
| The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. B Santomasso, C Bachier, J Westin, K Rezvani, EJ Shpall American Society of Clinical Oncology educational book. American Society of …, 2019 | 310 | 2019 |
| Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin … A Younes, C Thieblemont, F Morschhauser, I Flinn, JW Friedberg, ... The Lancet Oncology 15 (9), 1019-1026, 2014 | 304 | 2014 |
| Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial NH Fowler, RE Davis, S Rawal, L Nastoupil, FB Hagemeister, ... The Lancet Oncology 15 (12), 1311-1318, 2014 | 303 | 2014 |
| Survival with axicabtagene ciloleucel in large B-cell lymphoma JR Westin, OO Oluwole, MJ Kersten, DB Miklos, MA Perales, A Ghobadi, ... New England Journal of Medicine 389 (2), 148-157, 2023 | 263 | 2023 |
| Steroid‐refractory acute GVHD: predictors and outcomes JR Westin, RM Saliba, M De Lima, A Alousi, C Hosing, MH Qazilbash, ... Advances in hematology 2011 (1), 601953, 2011 | 253 | 2011 |
| Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA DM Kurtz, J Soo, L Co Ting Keh, S Alig, JJ Chabon, BJ Sworder, A Schultz, ... Nature biotechnology 39 (12), 1537-1547, 2021 | 251 | 2021 |
| Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial ML Wang, H Lee, H Chuang, N Wagner-Bartak, F Hagemeister, J Westin, ... The Lancet Oncology 17 (1), 48-56, 2016 | 245 | 2016 |
| Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma CC Pinnix, JR Gunther, BS Dabaja, P Strati, P Fang, MC Hawkins, ... Blood advances 4 (13), 2871-2883, 2020 | 220 | 2020 |